TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06546553
Drug: PF-07826390
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors
Study: NCT05375435
Drug: dual-therapy
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
Study: NCT03988998
Drug: Radiofrequency ablation with radiotherapy
Normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiofrequency ablation with radiotherapy
Study: NCT04827589
Drug: Tirabrutinib
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06329674
Drug: A51R2
Normalized name: Amoxicillin/Clavulanic Acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT06329674
Drug: A51R3
Normalized name: Amoxicillin/Clavulanic Acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT06385847
Drug: Zoladex
Normalized name: Zoladex
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received 3.6 mg subcutaneous Zoladex
Study: NCT05222035
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor: Camrelizumab, 200 mg, intravenously (IV) , Day 1, Q3W, until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years).
Study: NCT05222035
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF: mecapegfilgrastim, 6 mg, subcutaneous injection, Day 1, Q3W, until stop using Camrelizumab, progressive disease (PD) or unacceptable toxicity.
Study: NCT05266014
Drug: tinlarebant
Normalized name: Tinlarebant
DrugBank: Tinlarebant (DB17832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months.
Study: NCT05024422
Drug: Cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Cabergoline (one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days)
Study: NCT04957329
Drug: Xalatan
Normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eye drop
Study: NCT04957329
Drug: Monoprost
Normalized name: dinoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eye drop
Study: NCT05097209
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
Study: NCT05097209
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
Study: NCT05097209
Drug: Induction Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
Study: NCT05097209
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Study: NCT05893680
Drug: Group that received placebo (PHYSIOLOGICAL SALINE ISOTONIC 9 mg/ml AMPULE)
Normalized name: sodium chloride 9 MG/ML [Broncho Saline]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The placebo effect has been demonstrated in various studies today. Some of these studies describe placebo analgesia. In this study, the placebo analgesic effect was investigated, and the child and parent were told that an analgesic was applied, but instead 2 cc of PF 0.9% ISOTONIC SODIUM CHLORIDE solution was intravenously administered.
Study: NCT06180941
Drug: magnesium sulfate.
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: magnesium sulfate as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Study: NCT06180941
Drug: clonidine.
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clonidine as adjuvant to bupivacaine in supraclavicular brachial plexus block in pediatrics.
Study: NCT00002122
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002122
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04699123
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg will be given IV every 3 weeks
Study: NCT04921878
Drug: Mitoxantrone Hydrochloride Liposome injection
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
Study: NCT05708300
Drug: Mepolizumab 100 MG [Nucala]
Normalized name: mepolizumab 100 MG [Nucala]
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous injection once a month
Study: NCT00269997
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06468267
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
Study: NCT00000850
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000850
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000902
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000902
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000902
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000902
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000902
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000902
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000902
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000902
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000959
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05722405
Drug: Ixazomib plus low-dose lenalidomide
Normalized name: ethinyl estradiol
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
Study: NCT05722405
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib alone
Study: NCT04674254
Drug: Bevacizumab Injection
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
Study: NCT06379113
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.
Study: NCT06379113
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg po qd.
Study: NCT05023967
Drug: Extended Release Metformin Hydrochloride
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06364176
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with losartan through week 12
Study: NCT05195892
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of alpelisib granule at 50 mg in fasted state
Study: NCT04169451
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
Study: NCT04933799
Drug: PF-06650833
Normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression.
Study: NCT05419115
Drug: SQIN-Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
Study: NCT00000349
Drug: Flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06624904
Drug: Losartan potassium 50mg
Normalized name: LOSARTAN POTASSIUM 50MG TAB,UD
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose losartan (50 mg), encapsulated identically to placebo.
Study: NCT06285942
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines
Study: NCT06285942
Drug: No Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Other DOACs through PEG or subcutaneous heparin or LMWH
Study: NCT05072262
Drug: Dexamethasone Ophthalmic
Normalized name: dexAMETHasone ophthalmic
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical dexamethasone 1 mg/ml (Spersadex)
Study: NCT04597099
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
Study: NCT04597099
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
Study: NCT04666922
Drug: BI 765080
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765080
Study: NCT00492414
Drug: Paroxetine CR
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05062837
Drug: Hepatectomy Combined With Camrelizumab and Apatinib
Normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
Study: NCT05856578
Drug: Mulberry Twig Alkaloid Tablet
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
Study: NCT05856578
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin 100mg po qd
Study: NCT05065190
Drug: nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nintedanib
Study: NCT05997459
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W
Study: NCT05242822
Drug: KIN-3248
Normalized name: KIN-3248
DrugBank: KIN-3248 (DB17587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIN-3248 will be administered orally once daily in 28-day cycles
Study: NCT00002293
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06248112
Drug: Sacubitril and Valsartan-Test product
Normalized name: valsartan and sacubitril
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India
Study: NCT06248112
Drug: Sacubitril and Valsartan-Reference product
Normalized name: valsartan and sacubitril
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
Study: NCT05294406
Drug: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
Study: NCT05342519
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: While rapamycin is not approved for the treatment of vitiligo, it has been found to be efficacious in stopping disease progression in animal models. Another recent study in humans showed that doses of 0.5cc daily of 0.001% of the topical formulation are able to achieve improvement in hypopigmented lesions of the skin at both the clinical and histological level. At this dose, improvement in cell function was observed regarding maintenance of proliferative potential and prevention of senescence, with avoidance of total inhibition of cell growth as has been seen at higher potencies used for immunosuppression.
Study: NCT05342519
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin is an immunosuppressant that works by inhibiting the mammalian target of rapamycin (mTOR) leading to inhibition of the cell cycle and antibody production. It has also been shown to promote expansion of Treg populations. Although studies evaluating alternative dosing for vitiligo are limited, topical rapamycin has previously been used to treat angiofibromas related to Tuberous Sclerosis, vascular malformations such as port-wine stains, and inflammatory lesions such as plaque psoriasis. In a 2019 meta-analysis, 38 out of 40 reports included used topical formulations of 1% or lower potency rapamycin; the majority of publications were focused on the treatment of Tuberous Sclerosis, where the median concentration of mTOR inhibition was 0.1% dosed twice daily.
Study: NCT06545812
Drug: Epidural steroid injection (ESI)
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive methods such as epidural steroid injection (ESI) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.
Study: NCT06020664
Drug: NOX-1416+SOC
Normalized name: NOX-700
DrugBank: NOX-700 (DB05464)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOX1416+SOC as provided in Arm/group description
Study: NCT04438382
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT04438382
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or PO
Study: NCT04991688
Drug: BOTOX-A
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
Study: NCT05122741
Drug: P2Y12 Potent Inhibitor + Aspirin for STEMI patients
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
Study: NCT05122741
Drug: Clopidogrel + Aspirin for CCS patients
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
Study: NCT00080041
Drug: Motexafin Gadolinium Injection
Normalized name: gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05286437
Drug: Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
Study: NCT06280495
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 IV on day 1
Study: NCT06280495
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IV infusion on day 1
Study: NCT06280495
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg IV infusion on day 1
Study: NCT00002163
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04431245
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study subjects will stop the antiviral therapy. Patients will be closely monitored every 6-8 weeks for virological flare and/or biochemical flare.
Study: NCT06547385
Drug: ONO-4578
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06547385
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06547385
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06547385
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05827770
Drug: Toripalimab combined with Temozolomide
Normalized name: Toripalimab
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Toripalimab combined with Temozolomide
Study: NCT06239324
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
Study: NCT06546358
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive either quetiapine or trazodone.
Study: NCT06546358
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive either quetiapine or trazodone.
Study: NCT05013515
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator.